Rhogam ultra filtered plus
Ended Awarded Last action
- Contract number
- N3594920F0004
- Awardee
-
Kedrion Biopharma Inc. UEI UN3DCKKLHSE7
- Awarding agency
-
Bureau of Medicine and Surgery
Department of the Navy, Department of Defense
- Obligated
- $6,944
Award facts
- Contract value 100% obligated
- $6,943.56 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Funding agency
- Defense Health Agency Department of Defense
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Fort Lee, NJ 07024, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $6,944 | |
| Other Administrative Action | $0 | |
| Original award | $0 |
About this award
The Defense Health Agency awarded a $6,943.56 delivery order to Kedrion Biopharma Inc. for RHOGAM Ultra Filtered Plus, a specialty pharmaceutical product used in immunohematology. This firm fixed-price delivery order was issued without set-aside provisions and is scheduled for completion by September 30, 2021, with performance taking place at Fort Lee, New Jersey. The award is issued against the GSA Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB), a streamlined contracting vehicle that enables the Department of Defense to efficiently procure specialty pharmaceutical products.
Kedrion Biopharma is a plasma derivative manufacturer specializing in therapies for rare and chronic conditions, including hemophilia and immune deficiencies. The company has an established relationship with the Defense Health Agency and other military medical commands through multiple delivery orders for RHOGAM products issued under the GSA schedule contract. In addition to its Defense Department business, Kedrion maintains significant federal supply agreements with the Department of Veterans Affairs, including a Blanket Purchase Agreement for Ryplazim with potential value exceeding $6 million through December 2024, and a multiple award Federal Supply Schedule contract with VA's Veterans Integrated Service Network 12 representing approximately $24 million in potential sales.
Quick answers
Who was awarded contract N3594920F0004?
N3594920F0004 was awarded to Kedrion Biopharma Inc. by Bureau of Medicine and Surgery (Department of the Navy) on October 1, 2020.
How much is contract N3594920F0004 worth?
The government has obligated $6,944 on N3594920F0004.
Which agency awarded contract N3594920F0004?
Bureau of Medicine and Surgery (Department of the Navy) awarded N3594920F0004, with funding from Defense Health Agency (Department of Defense).
Is contract N3594920F0004 an order under another contract?
Yes. N3594920F0004 is a delivery order under V797D30219, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract N3594920F0004 competed?
The extent of competition for N3594920F0004 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award